ORF6, a repressor of the MHC class I pathway: new molecular target for SARS-CoV-2 drug discovery?

References

• Natarajan K, Li H, Mariuzza RA, et al. MHC class I molecules, structure and function. Rev Immunogenet. 1999;1(1):32–46.
   PubMedGoogle Scholar
• Kuenzel S, Till A, Winkler M, et al. The nucleotide-binding oligomerization domain-like receptor NLRC5 is involved in IFN-dependent antiviral immune responses. J Immunol. 2010 Feb 15;184(4):1990–2000.
   PubMed Web of Science ®Google Scholar
• Meissner TB, Li A, Kobayashi KS. NLRC5: a newly discovered MHC class I transactivator (CITA). Microbes Infect. 2012 Jun;14(6):477–484. doi: 10.1016/j.micinf.2011.12.007
   PubMed Web of Science ®Google Scholar
• Meissner TB, Li A, Liu YJ, et al. The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity. Biochem Biophys Res Commun. 2012 Feb 24;418(4):786–791.
   PubMed Web of Science ®Google Scholar
• Meissner TB, Liu YJ, Lee KH, et al. NLRC5 cooperates with the RFX transcription factor complex to induce MHC class I gene expression. J Immunol. 2012 May 15;188(10):4951–4958.
   PubMed Web of Science ®Google Scholar
• Bedford J, Enria D, Giesecke J, et al. COVID-19: towards controlling of a pandemic. Lancet. 2020;395(10229):1015–1018. doi: 10.1016/S0140-6736(20)30673-5
   PubMed Web of Science ®Google Scholar
• Park A, Iwasaki A. Type I and type III interferons – induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 2020 Jun 10;27(6):870–878.
   PubMed Web of Science ®Google Scholar
• Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020 May 28;181(5):1036–1045 e9.
   PubMed Web of Science ®Google Scholar
• Konno Y, Kimura I, Uriu K, et al. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant. Cell Rep. 2020;32(12):108185. doi: 10.1016/j.celrep.2020.108185
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang XM, Li SR, et al. NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat Commun. 2019 Apr 3;10(1):1507.
   PubMedGoogle Scholar
• Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020 May;17(5):533–535. doi: 10.1038/s41423-020-0402-2
   PubMed Web of Science ®Google Scholar
• Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1. Nature. 1995 Jun 22;375(6533):685–688.
   PubMed Web of Science ®Google Scholar
• Sorel O, Chen T, Myster F, et al. Macavirus latency-associated protein evades immune detection through regulation of protein synthesis in cis depending upon its glycin/glutamate-rich domain. PLOS Pathogens. 2017 Oct;13(10):e1006691. doi: 10.1371/journal.ppat.1006691
   PubMed Web of Science ®Google Scholar
• Hill A, Jugovic P, York I, et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature. 1995 Jun 1;375(6530):411–415.
   PubMed Web of Science ®Google Scholar
• Ahn K, Gruhler A, Galocha B, et al. The ER-Luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity. 1997;6(5):613–621. doi: 10.1016/S1074-7613(00)80349-0
   PubMed Web of Science ®Google Scholar
• Schwartz O, Marechal V, Le Gall S, et al. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV–1 Nef protein. Nat Med. 1996 Mar;2(3):338–342. doi: 10.1038/nm0396-338
   PubMed Web of Science ®Google Scholar
• Reusch U, Muranyi W, Lucin P, et al. A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation. EMBO J. 1999 Feb 15;18(4):1081–1091.
   PubMed Web of Science ®Google Scholar
• Chatterjee-Kishore M, van Den Akker F, Stark GR. Adenovirus E1A down-regulates LMP2 transcription by interfering with the binding of stat1 to IRF1. J Biol Chem. 2000 Jul 7;275(27):20406–20411.
   PubMed Web of Science ®Google Scholar
• Menachery VD, Schafer A, Burnum-Johnson KE, et al. MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. Proc Natl Acad Sci, USA. 2018 Jan 30;115(5):E1012–E1021.
   PubMed Web of Science ®Google Scholar
• Lieberman NAP, Peddu V, Xie H, et al. In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age. PLoS Biol. 2020 Sep;18(9):e3000849. doi: 10.1371/journal.pbio.3000849
   PubMed Web of Science ®Google Scholar
• Yoo JS, Sasaki M, Cho SX, et al. SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis. Nat Commun. 2021 Nov 15;12(1):6602.
   PubMed Web of Science ®Google Scholar
• Ravindra NG, Alfajaro MM, Gasque V, et al. Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell state changes. PLoS Biol. 2021 Mar;19(3):e3001143. doi: 10.1371/journal.pbio.3001143
   PubMed Web of Science ®Google Scholar
• Arshad N, Laurent-Rolle M, Ahmed WS, et al. SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to downregulate MHC-I surface expression. bioRxiv: The Preprint Server For Biology. 2022 May 17. doi: 10.1101/2022.05.17.492198
   Google Scholar
• Zhang Y, Chen Y, Li Y, et al. The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Ι. Proc Natl Acad Sci, USA. 2021 Jun 8;118(23): doi: 10.1073/pnas.2024202118
   Web of Science ®Google Scholar
• Yoshihama S, Roszik J, Downs I, et al. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci, USA. 2016 May 24;113(21):5999–6004.
   PubMed Web of Science ®Google Scholar
• Chelbi ST, Guarda G. NLRC5, a promising new entry in tumor immunology. J Immunother Cancer. 2016;4(1):39. doi: 10.1186/s40425-016-0143-z
   PubMedGoogle Scholar
• Yoshihama S, Vijayan S, Sidiq T, et al. NLRC5/CITA: a key Player in cancer immune surveillance. Trends Cancer. 2017 Jan;3(1):28–38. doi: 10.1016/j.trecan.2016.12.003
   PubMed Web of Science ®Google Scholar
• Narayanan A, Narwal M, Majowicz SA, et al. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. Commun Biol. 2022 Feb 25;5(1):169.
   PubMed Web of Science ®Google Scholar
• Liu H, Iketani S, Zask A, et al. Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat Commun. 2022 Apr 7;13(1):1891.
   PubMed Web of Science ®Google Scholar
• Al-Karmalawy AA, El-Gamil DS, El-Shesheny R, et al. Design and statistical optimisation of emulsomal nanoparticles for improved anti-SARS-CoV-2 activity of N-(5-nitrothiazol-2-yl)-carboxamido candidates: in vitro and in silico studies. J Enzyme Inhib Med Chem. 2023 Dec;38(1):2202357. doi: 10.1080/14756366.2023.2202357
   PubMed Web of Science ®Google Scholar
• Jan JT, Cheng TR, Juang YP, et al. Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection. Proc Natl Acad Sci, USA. 2021 Feb 2;118(5): doi: 10.1073/pnas.2021579118
   Web of Science ®Google Scholar
• Fuzimoto AD, Isidoro C. The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - additional weapons in the fight against the COVID-19 pandemic? J Tradit Complement Med. 2020 Jul;10(4):405–419. doi: 10.1016/j.jtcme.2020.05.003
   PubMedGoogle Scholar
• Gao LQ, Xu J, Chen SD. In silico screening of potential Chinese herbal medicine against COVID-19 by targeting SARS-CoV-2 3CLpro and Angiotensin converting enzyme II using molecular docking. Chin J Integr Med. 2020 Jul;26(7):527–532. doi: 10.1007/s11655-020-3476-x
   PubMed Web of Science ®Google Scholar
• Chang YC, Yang CF, Chen YF, et al. A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant. EMBO Mol Med. 2022 Apr 7;14(4):e15298.
   PubMed Web of Science ®Google Scholar
• Phan T. Genetic diversity and evolution of SARS-CoV-2. Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases. Infect Genet Evol. 2020 Jul;81:104260. doi: 10.1016/j.meegid.2020.104260
   PubMed Web of Science ®Google Scholar
• Pillay TS. Gene of the month: the 2019-nCov/SARS-CoV-2 novel coronavirus spike protein. J Clin Pathol. 2020 Jul;73(7):366–369. doi: 10.1136/jclinpath-2020-206658
   PubMed Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020 Apr 16;181(2):281–292 e6.
   PubMed Web of Science ®Google Scholar
• Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020 May;10(5):766–788. doi: 10.1016/j.apsb.2020.02.008
   PubMed Web of Science ®Google Scholar
• Medeiros IG, Khayat AS, Stransky B, et al. A small interfering RNA (siRNA) database for SARS-CoV-2. Sci Rep. 2021 Apr 23;11(1):8849.
   PubMed Web of Science ®Google Scholar
• Saadat K. RNAi-mediated siRNA sequences to combat the COVID-19 pandemic with the inhibition of SARS-CoV2. Gene Rep. 2022 Mar;26:101512. doi: 10.1016/j.genrep.2022.101512
   PubMed Web of Science ®Google Scholar
• Li JY, Liao CH, Wang Q, et al. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus res. 2020 Sep;286:198074.
   PubMed Web of Science ®Google Scholar
• Lei X, Dong X, Ma R, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun. 2020 Jul 30;11(1):3810.
   PubMed Web of Science ®Google Scholar
• Xia H, Cao Z, Xie X, et al. Evasion of type I interferon by SARS-CoV-2. Cell Rep. 2020 Oct 6;33(1):108234.
   PubMed Web of Science ®Google Scholar
• Miorin L, Kehrer T, Sanchez-Aparicio MT, et al. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc Natl Acad Sci, USA. 2020 Nov 10;117(45):28344–28354.
   PubMed Web of Science ®Google Scholar
• Addetia A, Lieberman NAP, Phung Q, et al. SARS-CoV-2 ORF6 disrupts bidirectional nucleocytoplasmic transport through interactions with Rae1 and Nup98. MBio. 2021 Apr 13;12(2): doi: 10.1128/mBio.00065-21
   Web of Science ®Google Scholar
• Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020 Jul;583(7816):459–468. doi: 10.1038/s41586-020-2286-9
   PubMed Web of Science ®Google Scholar
• van de Leemput J, Han Z. Understanding individual SARS-CoV-2 proteins for targeted drug development against COVID-19. Mol Cell Biol. 2021 Aug 24;41(9):e0018521.
   PubMed Web of Science ®Google Scholar
• Zhu JY, Lee JG, van de Leemput J, et al. Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with selinexor as an effective treatment. Cell Biosci. 2021 Mar 25;11(1):59.
   PubMed Web of Science ®Google Scholar
• Tripathi PP, Arami H, Banga I, et al. Cell penetrating peptides in preclinical and clinical cancer diagnosis and therapy. Oncotarget. 2018 Dec 14;9(98):37252–37267.
   PubMedGoogle Scholar